Yi Xu

ORCID: 0000-0002-6917-184X · 4 papers in corpus
article 2026
Clinically Validated Leptin Receptor as a Target for Liposomal Delivery of Metformin in Endometriosis Therapy
ACS nano ·doi:10.1021/acsnano.5c18417

Endometriosis is a common, estrogen-driven chronic gynecologic disorder defined by the ectopic growth of endometrial-like tissue within the peritoneal cavity. Existing treatment options, primarily surgery and hormonal therapy, are limited b…

article 2026
Machine learning-integrated molecular subtyping reveals two biologically distinct endometriosis subtypes in the EndometDB database
Computational biology and chemistry ·doi:10.1016/j.compbiolchem.2026.109349

BACKGROUND: Endometriosis affects approximately 10% of reproductive-age women, with a diagnostic delay of 7-10 years. Despite clinical heterogeneity, current rASRM staging poorly predicts treatment outcomes. Molecular subtyping may reveal b…

article 2022
Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women
Frontiers in pharmacology ·doi:10.3389/fphar.2022.1027648

Background: Treatment with gonadotropin-releasing hormone (GnRH) antagonists is a powerful strategy to suppress gonadotropin activity in women with sex hormone-dependent disorders. Herein, we provide the safety, pharmacokinetics (PK), and p…

article 2010
Expression and significance of serum MMP-9 in patients with endometriosis

Objective:To detect the level of serum matrix metalloproteinases-9 (MMP-9) in patients with endometriosis,explore the effect and significance of MMP-9 in endometriosis.Methods:Serum samples of 35 patients with endometriosis were collected,i…